pomalidomide news

All news on pomalidomide (also known as Pomalyst, Imnovid, and 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione): plants, production capacities, investments and involved companies.

13 June 2026

Johnson & Johnson: TALVEY plus DARZALEX FASPRO shows superior PFS and OS in Phase 3 MonumenTAL‑3

GPRC5D bispecific plus anti‑CD38 combo cut progression risk and delivered 24‑month PFS up to 81% and OS up to 89% in earlier‑line relapsed/refractory multiple myeloma.
29 May 2026

Johnson & Johnson: TECVAYLI improves PFS and OS in second-line multiple myeloma

Phase 3 MajesTEC‑9: teclistamab cut progression/death risk 71% (HR 0.29) and death 40% (HR 0.60) vs PVd/Kd in early RRMM; higher ≥CR (65.9% vs 16.8%); infections and CRS increased

Who will be producing pomalidomide in the future?

Find out with chemXplore Alpha

Learn more